 between
0% and 0.4%.41

Table XXXVIII. Evidence to decision framework: Pharmacoprophylaxis after endovenous ablation
Domain
How substantial are desirable effects of
the strategy?
How substantial are the undesirable
anticipated effects?

Evidence/Panel input
Routine thromboprophylaxis appears to reduce the risk of
postprocedural thrombotic events, but the data is heterogenous and
the magnitude of effect is low.
Low